title: Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane.
abstract: Metastatic breast cancer is currently incurable and the goals of therapy focus on prolonging survival and maintaining quality of life by controlling symptoms and minimizing toxicity. Treatments for metastatic breast cancer include chemotherapeutic agents from various classes, such as taxanes, vinca alkaloids, anthracyclines and antimetabolites. This review provides an overview of chemotherapeutic agents for the treatment of metastatic breast cancer patients previously treated with anthracyclines and taxanes, focusing on a clinical evaluation of eribulin, the most recently approved agent for the treatment of metastatic breast cancer. Eribulin is a synthetic derivative of halichondrin B, a tumour growth inhibitor found in marine sponges, which prevents microtubule growth and sequesters the tubulin molecules into unusual aggregates, initiating apoptosis. Studies of eribulin have shown that the drug is effective in the treatment of previously treated metastatic breast cancer, and has an acceptable toxicity profile. Importantly, in the phase III EMBRACE study, eribulin treatment resulted in a survival advantage, a difficult endpoint to achieve with a single chemotherapeutic agent. An additional phase III study showed that eribulin has similar efficacy to capecitabine in women treated with no more than three prior therapies. Furthermore, pre-specified exploratory analyses suggest that particular patient subgroups may have greater therapeutic benefit with eribulin and may warrant further study to explore the potential mechanisms.
authors: Department of Target Therapy Oncology, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan, ss-saji@wa2.so-net.ne.jp.
authors: Shigehira
authors: S
authors: Saji
mesh_terms: D018943:Anthracyclines / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D005663:Furans / Q000627:therapeutic use; D006801:Humans; D007659:Ketones / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use*; D000095662:Polyether Polyketides
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D005663:Furans; D007659:Ketones; D043823:Taxoids; C080625:taxane; C490954:eribulin; D000095662:Polyether Polyketides
references: Clin Cancer Res. 2009 Jun 15;15(12):4207-12
references: 19509177
references: Breast Cancer Res Treat. 2008 Jan;107(2):275-9
references: 17380382
references: Biochemistry. 2010 Feb 16;49(6):1331-7
references: 20030375
references: Mol Cancer Ther. 2005 Jul;4(7):1086-95
references: 16020666
references: J Clin Oncol. 2010 Sep 1;28(25):3922-8
references: 20679609
references: Ann Oncol. 2012 Jun;23(6):1441-8
references: 21989327
references: Ann Oncol. 2012 Aug;23 Suppl 6:vi46-51
references: 23012302
references: Lancet. 2011 Mar 12;377(9769):914-23
references: 21376385
references: Ann Pharmacother. 2001 Feb;35(2):217-27
references: 11215843
references: Adv Ther. 2011 Nov;28(11):973-85
references: 22020735
references: J Clin Oncol. 2009 Jun 20;27(18):2954-61
references: 19349550
references: Ann Oncol. 2010 May;21 Suppl 5:v15-9
references: 20555067
references: Anticancer Drugs. 2010 Nov;21(10):885-9
references: 20838209
references: Invest New Drugs. 2012 Oct;30(5):1926-33
references: 21887501
references: Crit Rev Oncol Hematol. 2006 Oct;60(1):59-75
references: 16806960
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Clin Cancer Res. 2009 Jun 15;15(12):4213-9
references: 19509146
references: Curr Oncol. 2012 Apr;19(2):91-105
references: 22514495
references: Nat Rev Clin Oncol. 2012 Jun 05;9(7):
references: 22665363
references: Biochem Biophys Res Commun. 2009 Jan 16;378(3):450-5
references: 19032935